Identification of novel α4β2-nicotinic acetylcholine receptor (nAChR) agonists based on an isoxazole ether scaffold that demonstrate antidepressant-like activity

Journal of Medicinal Chemistry

Volumn 55, Issue 2, 2012, Pages 812-823

  Yu, Li Fang ^a   Tückmantel, Werner ^c   Eaton, J Brek ^b   Caldarone, Barbara ^c   Fedolak, Allison ^c   Hanania, Taleen ^c   Brunner, Dani ^c,d   Lukas, Ronald J ^b   Kozikowski, Alan P ^a  

^a UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^b BARROW NEUROLOGICAL INSTITUTE   (United States)

^c PSYCHOGENICS INC   (United States)

^d NYSPI ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3 (ANILINOMETHYL) 5 [(2 AZETIDINYL)METHOXY]ISOXAZOLE; 3 (PHENOXYMETHYL) 5 [(2 PYRROLIDINYL)METHOXY]ISOXAZOLE; 3 [(2 AZETIDINYL)METHOXY] 5 (PHENOXYMETHYL)ISOXAZOLE; 3 [(2 AZETIDINYL)METHOXY] 5 [(CYCLOPROPYLMETHOXY)METHYL]ISOXAZOLE; 3 [(2 AZETIDINYL)METHOXY] 5 [(HEXYLOXY)METHYL]ISOXAZOLE; 3 [(2 AZETIDINYL)METHOXY] 5 ISOXAZOLYLMETHANOL; 3 [(2 AZETIDINYL)METHOXY] 5 METHYLISOXAZOLE; 3 METHYL 5 [(2 PYRROLIDINYL)METHOXY]ISOXAZOLE; 5 [(2 AZETIDINYL)METHOXY] 3 (FLUOROMETHYL)ISOXAZOLE TRIFLUOROACETATE; 5 [(2 AZETIDINYL)METHOXY] 3 (PHENOXYMETHYL)ISOXAZOLE; 5 [(2 AZETIDINYL)METHOXY] 3 [(4 FLUOROANILINO)METHYL]ISOXAZOLE; 5 [(2 AZETIDINYL)METHOXY] 3 [(N ETHYLCARBAMOYLOXY)METHYL]ISOXAZOLE; 5 [(2 AZETIDINYL)METHOXY] 3 [(N PHENYLCARBAMOYLOXY)METHYL]ISOXAZOLE; 5 [(2 AZETIDINYL)METHOXY] 3 ISOXAZOLYLMETHANOL; 5 [(2 AZETIDINYL)METHOXY] 3 METHYLISOXAZOLE; 5 [(2-AZETIDINYL)METHOXY] 3 [(N CYCLOPENTYLCARBAMOYLOXY)METHYL]ISOXAZOLE; ANTIDEPRESSANT AGENT; CYTOCHROME P450; ISOXAZOLE DERIVATIVE; NEUROTRANSMITTER RECEPTOR; NICOTINE; NICOTINIC AGENT; NICOTINIC RECEPTOR ALPHA4BETA2; POTASSIUM CHANNEL HERG; SERTRALINE; TRANSCRIPTION FACTOR ERG; UNCLASSIFIED DRUG; VARENICLINE;

ANIMAL EXPERIMENT; ANTIDEPRESSANT ACTIVITY; ARTICLE; BINDING AFFINITY; CONTROLLED STUDY; DRUG ABSORPTION; DRUG DESIGN; DRUG DISTRIBUTION; DRUG EXCRETION; DRUG METABOLISM; DRUG PROTEIN BINDING; DRUG RECEPTOR BINDING; DRUG SYNTHESIS; ENZYME INHIBITION; HUMAN; HUMAN CELL; LIGAND BINDING; LIVER MICROSOME METABOLISM; MALE; MOUSE; NONHUMAN; STRUCTURE ACTIVITY RELATION; TOXICITY TESTING;

ANIMALS; ANTIDEPRESSIVE AGENTS; BLOOD PROTEINS; CYTOCHROME P-450 ENZYME SYSTEM; ETHER-A-GO-GO POTASSIUM CHANNELS; HEK293 CELLS; HUMANS; ISOXAZOLES; MALE; MICE; MICE, INBRED BALB C; MICROSOMES, LIVER; NICOTINIC AGONISTS; PROTEIN BINDING; RADIOLIGAND ASSAY; RATS; RECEPTORS, NICOTINIC; STEREOISOMERISM; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84856405602     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm201301h     Document Type: Article

References (57)

1. Changeux, J. P. Nicotine addiction and nicotinic receptors: lessons from genetically modified mice Nat. Rev. Neurosci. 2010, 11, 389-401
2. Unwin, N. Refined structure of the nicotinic acetylcholine receptor at 4 Å resolution J. Mol. Biol. 2005, 346, 967-989 (Pubitemid 40215523)
3. Gotti, C.; Clementi, F.; Fornari, A.; Gaimarri, A.; Guiducci, S.; Manfredi, I.; Moretti, M.; Pedrazzi, P.; Pucci, L.; Zoli, M. Structural and functional diversity of native brain neuronal nicotinic receptors Biochem. Pharmacol. 2009, 78, 703-711
4. Jensen, A. A.; Frolund, B.; Liljefors, T.; Krogsgaard-Larsen, P. Neuronal nicotinic acetylcholine receptors: structural revelations, target identifications, and therapeutic inspirations J. Med. Chem. 2005, 48, 4705-4745 (Pubitemid 41038456)
5. Gotti, C.; Clementi, F. Neuronal nicotinic receptors: from structure to pathology Prog. Neurobiol. 2004, 74, 363-396 (Pubitemid 40092737)
6. Romanelli, M. N.; Gratteri, P.; Guandalini, L.; Martini, E.; Bonaccini, C.; Gualtieri, F. Central nicotinic receptors: structure, function, ligands, and therapeutic potential ChemMedChem 2007, 2, 746-767
7. Taly, A.; Corringer, P. J.; Guedin, D.; Lestage, P.; Changeux, J. P. Nicotinic receptors: allosteric transitions and therapeutic targets in the nervous system Nat. Rev. Drug Discovery 2009, 8, 733-750
8. Arneric, S. P.; Holladay, M.; Williams, M. Neuronal nicotinic receptors: a perspective on two decades of drug discovery research Biochem. Pharmacol. 2007, 74, 1092-1101 (Pubitemid 47417924)
9. Mihalak, K. B.; Carroll, F. I.; Luetje, C. W. Varenicline is a partial agonist at alpha4beta2 and a full agonist at alpha7 neuronal nicotinic receptors Mol. Pharmacol. 2006, 70, 801-805 (Pubitemid 44268437)
10. Coe, J. W.; Brooks, P. R.; Vetelino, M. G.; Wirtz, M. C.; Arnold, E. P.; Huang, J.; Sands, S. B.; Davis, T. I.; Lebel, L. A.; Fox, C. B.; Shrikhande, A.; Heym, J. H.; Schaeffer, E.; Rollema, H.; Lu, Y.; Mansbach, R. S.; Chambers, L. K.; Rovetti, C. C.; Schulz, D. W.; Tingley, F. D., 3rd; O'Neill, B. T. Varenicline: an alpha4beta2 nicotinic receptor partial agonist for smoking cessation J. Med. Chem. 2005, 48, 3474-3477 (Pubitemid 40664098)
11. Philip, N. S.; Carpenter, L. L.; Tyrka, A. R.; Price, L. H. Nicotinic acetylcholine receptors and depression: a review of the preclinical and clinical literature Psychopharmacology (Berlin, Ger.) 2010, 212, 1-12
12. Mineur, Y. S.; Picciotto, M. R. Nicotine receptors and depression: revisiting and revising the cholinergic hypothesis Trends Pharmacol. Sci. 2010, 31, 580-586
13. Shytle, R. D.; Silver, A. A.; Lukas, R. J.; Newman, M. B.; Sheehan, D. V.; Sanberg, P. R. Nicotinic acetylcholine receptors as targets for antidepressants Mol. Psychiatry 2002, 7, 525-535
14. Caldarone, B. J.; Wang, D.; Paterson, N. E.; Manzano, M.; Fedolak, A.; Cavino, K.; Kwan, M.; Hanania, T.; Chellappan, S. K.; Kozikowski, A. P.; Olivier, B.; Picciotto, M. R.; Ghavami, A. Dissociation between duration of action in the forced swim test in mice and nicotinic acetylcholine receptor occupancy with sazetidine, varenicline, and 5-I-A85380 Psychopharmacology (Berlin, Ger.) 2011, 217, 199-210
15. Janowsky, D. S.; el-Yousef, M. K.; Davis, J. M.; Sekerke, H. J. A cholinergic-adrenergic hypothesis of mania and depression Lancet 1972, 2, 632-635
16. George, T. P.; Sacco, K. A.; Vessicchio, J. C.; Weinberger, A. H.; Shytle, R. D. Nicotinic antagonist augmentation of selective serotonin reuptake inhibitor-refractory major depressive disorder: a preliminary study J. Clin. Psychopharmacol. 2008, 28, 340-344
17. Drevets, W. C.; Furey, M. L. Replication of scopolamine's antidepressant efficacy in major depressive disorder: a randomized, placebo-controlled clinical trial Biol. Psychiatry 2010, 67, 432-438
18. Furey, M. L.; Drevets, W. C. Antidepressant efficacy of the antimuscarinic drug scopolamine: a randomized, placebo-controlled clinical trial Arch. Gen. Psychiatry 2006, 63, 1121-1129 (Pubitemid 44498391)
19. Overstreet, D. H. Selective breeding for increased cholinergic function: development of a new animal model of depression Biol. Psychiatry 1986, 21, 49-58 (Pubitemid 16043733)
20. Pucilowski, O.; Overstreet, D. H.; Rezvani, A. H.; Janowsky, D. S. Chronic mild stress-induced anhedonia: greater effect in a genetic rat model of depression Physiol. Behav. 1993, 54, 1215-1220 (Pubitemid 23343148)
21. Caldarone, B. J.; Harrist, A.; Cleary, M. A.; Beech, R. D.; King, S. L.; Picciotto, M. R. High-affinity nicotinic acetylcholine receptors are required for antidepressant effects of amitriptyline on behavior and hippocampal cell proliferation Biol. Psychiatry 2004, 56, 657-664 (Pubitemid 39446847)
22. Mineur, Y. S.; Somenzi, O.; Picciotto, M. R. Cytisine, a partial agonist of high-affinity nicotinic acetylcholine receptors, has antidepressant-like properties in male C57BL/6J mice Neuropharmacology 2007, 52, 1256-1262 (Pubitemid 46527701)
23. Buckley, M. J.; Surowy, C.; Meyer, M.; Curzon, P. Mechanism of action of A-85380 in an animal model of depression Prog. Neuropsychopharmacol. Biol. Psychiatry 2004, 28, 723-730 (Pubitemid 38987398)
24. Rollema, H.; Guanowsky, V.; Mineur, Y. S.; Shrikhande, A.; Coe, J. W.; Seymour, P. A.; Picciotto, M. R. Varenicline has antidepressant-like activity in the forced swim test and augments sertraline's effect Eur. J. Pharmacol. 2009, 605, 114-116
25. Lippiello, P. M.; Beaver, J. S.; Gatto, G. J.; James, J. W.; Jordan, K. G.; Traina, V. M.; Xie, J.; Bencherif, M. TC-5214 (S -(+)-mecamylamine): a neuronal nicotinic receptor modulator with antidepressant activity CNS Neurosci. Ther. 2008, 14, 266-277
26. Gong, C. L.; Chiu, Y. T.; Lin, N. N.; Cheng, C. C.; Lin, S. Z.; Lee, T. J.; Kuo, J. S. Regulation of the common carotid arterial blood flow by nicotinic receptors in the medulla of cats Br. J. Pharmacol. 2006, 149, 206-214 (Pubitemid 44360102)
27. Shytle, R. D.; Silver, A. A.; Sheehan, K. H.; Sheehan, D. V.; Sanberg, P. R. Neuronal nicotinic receptor inhibition for treating mood disorders: preliminary controlled evidence with mecamylamine Depression Anxiety 2002, 16, 89-92 (Pubitemid 35334663)
28. Papke, R. L.; Sanberg, P. R.; Shytle, R. D. Analysis of mecamylamine stereoisomers on human nicotinic receptor subtypes J. Pharmacol. Exp. Ther. 2001, 297, 646-656 (Pubitemid 32377996)
29. Elliott, R. L.; Ryther, K. B.; Anderson, D. J.; Raszkiewicz, J. L.; Campbell, J. E.; Sullivan, J. P.; Garvey, D. S. Phenyl pyrrolidine analogues as potent nicotinic acetylcholine receptor (nAChR) ligands Bioorg. Med. Chem. Lett. 1995, 5, 991-996
30. Guandalini, L.; Martini, E.; Dei, S.; Manetti, D.; Scapecchi, S.; Teodori, E.; Romanelli, M. N.; Varani, K.; Greco, G.; Spadola, L.; Novellino, E. Design of novel nicotinic ligands through 3D database searching Bioorg. Med. Chem. 2005, 13, 799-807 (Pubitemid 40093622)
31. Elliott, R. L.; Ryther, K. B.; Anderson, D. J.; Piattoni-Kaplan, M.; Kuntzweiler, T. A.; Donnelly-Roberts, D.; Arneric, S. P.; Holladay, M. W. Novel 2-(2′-furo[3,2-b]pyridinyl) pyrrolidines: potent neuronal nicotinic acetylcholine receptor ligands Bioorg. Med. Chem. Lett. 1997, 7, 2703-2708 (Pubitemid 27472814)
32. Efange, S. M.; Tu, Z.; von Hohenberg, K.; Francesconi, L.; Howell, R. C.; Rampersad, M. V.; Todaro, L. J.; Papke, R. L.; Kung, M. P. 2-(2-Piperidyl)- and 2-(2-pyrrolidyl)chromans as nicotine agonists: synthesis and preliminary pharmacological characterization J. Med. Chem. 2001, 44, 4704-4715 (Pubitemid 33144480)
33. Garvey, D. S.; Wasicak, J. T.; Decker, M. W.; Brioni, J. D.; Buckley, M. J.; Sullivan, J. P.; Carrera, G. M.; Holladay, M. W.; Arneric, S. P.; Williams, M. Novel isoxazoles which interact with brain cholinergic channel receptors have intrinsic cognitive enhancing and anxiolytic activities J. Med. Chem. 1994, 37, 1055-1059 (Pubitemid 24145365)
34. Garvey, D. S.; Wasicak, J. T.; Elliott, R. L.; Lebold, S. A.; Hettinger, A. M.; Carrera, G. M.; Lin, N. H.; He, Y.; Holladay, M. W.; Anderson, D. J. Ligands for brain cholinergic channel receptors: synthesis and in vitro characterization of novel isoxazoles and isothiazoles as bioisosteric replacements for the pyridine ring in nicotine J. Med. Chem. 1994, 37, 4455-4463
35. Lin, N.-H.; He, Y.; David, J, A.; Wasicak, J. T.; Kasson, R.; Sweeny, D.; James, P, S. Synthesis and structure-activity relationships of pyrrolidine-modified analogs of the potent cholinergic channel activator, ABT 418 Bioorg. Med. Chem. Lett. 1994, 4, 2389-2394 (Pubitemid 24324546)
36. Lin, N.-H.; He, Y.; Arneric, S. P.; Sullivan, J. P. Synthesis and structure-activity relationships of 2′-(R) and (S) pyrrolidine-modified analogs of the cholinergic channel activator, ABT-418 Bioorg. Med. Chem. Lett. 1995, 5, 1141-1146
37. Avenoza, A.; Busto, J. H.; Cativiela, C.; Dordal, A.; Frigola, J.; Peregrina, J. M. Synthesis, activity and theoretical study of ABT-418 analogues Tetrahedron 2002, 58, 4505-4511 (Pubitemid 34522043)
38. Potter, A.; Corwin, J.; Lang, J.; Piasecki, M.; Lenox, R.; Newhouse, P. A. Acute effects of the selective cholinergic channel activator (nicotinic agonist) ABT-418 in Alzheimer's disease Psychopharmacology (Berlin, Ger.) 1999, 142, 334-342 (Pubitemid 29187621)
39. Badio, B.; Garraffo, H. M.; Plummer, C. V.; Padgett, W. L.; Daly, J. W. Synthesis and nicotinic activity of epiboxidine: an isoxazole analogue of epibatidine Eur. J. Pharmacol. 1997, 321, 189-194 (Pubitemid 27089550)
40. Fitch, R. W.; Pei, X. F.; Kaneko, Y.; Gupta, T.; Shi, D.; Federova, I.; Daly, J. W. Homoepiboxidines: further potent agonists for nicotinic receptors Bioorg. Med. Chem. 2004, 12, 179-190 (Pubitemid 38096230)
41. Tonder, J. E.; Hansen, J. B.; Begtrup, M.; Pettersson, I.; Rimvall, K.; Christensen, B.; Ehrbar, U.; Olesen, P. H. Improving the nicotinic pharmacophore with a series of (Isoxazole)methylene-1-azacyclic compounds: synthesis, structure-activity relationship, and molecular modeling J. Med. Chem. 1999, 42, 4970-4980
42. Abreo, M. A.; Lin, N. H.; Garvey, D. S.; Gunn, D. E.; Hettinger, A. M.; Wasicak, J. T.; Pavlik, P. A.; Martin, Y. C.; Donnelly-roberts, D. L.; Anderson, D. J.; Sullivan, J. P.; Williams, M.; Arneric, S. P.; Holladay, M. W. Novel 3-Pyridyl ethers with subnanomolar affinity for central neuronal nicotinic acetylcholine receptors J. Med. Chem. 1996, 39, 817-825 (Pubitemid 26069777)
43. Sullivan, J. P.; Donnelly-Roberts, D.; Briggs, C. A.; Anderson, D. J.; Gopalakrishnan, M.; Piattoni-Kaplan, M.; Campbell, J. E.; McKenna, D. G.; Molinari, E.; Hettinger, A. M.; Garvey, D. S.; Wasicak, J. T.; Holladay, M. W.; Williams, M.; Arneric, S. P. A-85380 [3-(2(S)-azetidinylmethoxy) pyridine]: in vitro pharmacological properties of a novel, high affinity alpha 4 beta 2 nicotinic acetylcholine receptor ligand Neuropharmacology 1996, 35, 725-734 (Pubitemid 26308549)
44. Koren, A. O.; Horti, A. G.; Mukhin, A. G.; Gundisch, D.; Kimes, A. S.; Dannals, R. F.; London, E. D. 2-, 5-, and 6-Halo-3-(2(S)-azetidinylmethoxy) pyridines: synthesis, affinity for nicotinic acetylcholine receptors, and molecular modeling J. Med. Chem. 1998, 41, 3690-3698 (Pubitemid 28449351)
45. Decker, M. W.; Meyer, M. D.; Sullivan, J. P. The therapeutic potential of nicotinic acetylcholine receptor agonists for pain control Expert Opin. Investig. Drugs 2001, 10, 1819-1830 (Pubitemid 32982808)
46. Decker, M. W.; Curzon, P.; Holladay, M. W.; Nikkel, A. L.; Bitner, R. S.; Bannon, A. W.; Donnelly-Roberts, D. L.; Puttfarcken, P. S.; Kuntzweiler, T. A.; Briggs, C. A.; Williams, M.; Arneric, S. P. The role of neuronal nicotinic acetylcholine receptors in antinociception: effects of ABT-594 J. Physiol. Paris 1998, 92, 221-224 (Pubitemid 29050938)
47. Wilens, T. E.; Decker, M. W. Neuronal nicotinic receptor agonists for the treatment of attention-deficit/hyperactivity disorder: focus on cognition Biochem. Pharmacol. 2007, 74, 1212-1223 (Pubitemid 47417927)
48. Marks, M. J.; Wageman, C. R.; Grady, S. R.; Gopalakrishnan, M.; Briggs, C. A. Selectivity of ABT-089 for alpha4beta2* and alpha6beta2* nicotinic acetylcholine receptors in brain Biochem. Pharmacol. 2009, 78, 795-802
49. Bunnelle, W. H.; Dart, M. J.; Schrimpf, M. R. Design of ligands for the nicotinic acetylcholine receptors: the quest for selectivity Curr. Top. Med. Chem. 2004, 4, 299-334 (Pubitemid 38849362)
50. Rollema, H.; Shrikhande, A.; Ward, K. M.; Tingley, F. D., 3rd; Coe, J. W.; O'Neill, B. T.; Tseng, E.; Wang, E. Q.; Mather, R. J.; Hurst, R. S.; Williams, K. E.; de Vries, M.; Cremers, T.; Bertrand, S.; Bertrand, D. Pre-clinical properties of the alpha4beta2 nicotinic acetylcholine receptor partial agonists varenicline, cytisine and dianicline translate to clinical efficacy for nicotine dependence Br. J. Pharmacol. 2010, 160, 334-345
51. Liu, J.; Eaton, J. B.; Caldarone, B.; Lukas, R. J.; Kozikowski, A. P. Chemistry and pharmacological characterization of novel nitrogen analogues of AMOP-H-OH (Sazetidine-A, 6-[5-(azetidin-2-ylmethoxy)pyridin-3-yl]hex-5-yn-1-ol) as alpha4beta2-nicotinic acetylcholine receptor-selective partial agonists J. Med. Chem. 2010, 53, 6973-6985
52. Wei, Z. L.; Xiao, Y.; Yuan, H.; Baydyuk, M.; Petukhov, P. A.; Musachio, J. L.; Kellar, K. J.; Kozikowski, A. P. Novel pyridyl ring C5 substituted analogues of epibatidine and 3-(1-methyl-2(S)-pyrrolidinylmethoxy)pyridine (A-84543) as highly selective agents for neuronal nicotinic acetylcholine receptors containing beta2 subunits J. Med. Chem. 2005, 48, 1721-1724 (Pubitemid 40396305)
53. Bunnelle, W. H.; Tietje, K. R.; Frost, J. M.; Peters, D.; Ji, J.; Li, T.; Scanio, M. J.; Shi, L.; Anderson, D. J.; Dyhring, T.; Gronlien, J. H.; Ween, H.; Thorin-Hagene, K.; Meyer, M. D. Octahydropyrrolo[3,4-c]pyrrole: a diamine scaffold for construction of either alpha4beta2 or alpha7-selective nicotinic acetylcholine receptor (nAChR) ligands. Substitutions that switch subtype selectivity J. Med. Chem. 2009, 52, 4126-4141
54. Gatto, G. J.; Bohme, G. A.; Caldwell, W. S.; Letchworth, S. R.; Traina, V. M.; Obinu, M. C.; Laville, M.; Reibaud, M.; Pradier, L.; Dunbar, G.; Bencherif, M. TC-1734: an orally active neuronal nicotinic acetylcholine receptor modulator with antidepressant, neuroprotective and long-lasting cognitive effects CNS Drug Rev. 2004, 10, 147-166 (Pubitemid 38879108)
55. Lukas, R. J.; Fryer, J. D.; Eaton, J. B.; Gentry, C. L. Some methods for studies of nicotinic acetylcholine receptor pharmacology. In Nicotinic Receptors and the Nervous System; Levin, E. D., Ed.; CRC Press: Boca Raton, FL, 2002; pp 3-27.
56. Lukas, R. J.; Norman, S. A.; Lucero, L. Characterization of nicotinic acetylcholine receptors expressed by cells of the SH-SY5Y human neuroblastoma clonal line Mol. Cell Neurosci. 1993, 4, 1-12 (Pubitemid 23070130)
57. Eaton, J. B.; Peng, J. H.; Schroeder, K. M.; George, A. A.; Fryer, J. D.; Krishnan, C.; Buhlman, L.; Kuo, Y. P.; Steinlein, O.; Lukas, R. J. Characterization of human alpha 4 beta 2-nicotinic acetylcholine receptors stably and heterologously expressed in native nicotinic receptor-null SH-EP1 human epithelial cells Mol. Pharmacol. 2003, 64, 1283-1294 (Pubitemid 37532218)